AGM Statement

Futura Medical PLC
07 May 2008



For immediate release                                               7 May 2008

                               Futura Medical Plc
                                        
                          ('Futura' or 'the Company')

                                 AGM Statement

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative
products for consumer healthcare, will hold its Annual General Meeting in London
later today.

At the meeting, Dr William Potter, the Company's Chairman, will make the
following statement:

'We have been pleased with progress across our product development portfolio in
the year to date. In respect of CSD500, the results of the clinical trial
completed last summer have been accepted by the Competent Authority as
supporting the proposed product claims and therefore no further clinical trials
are anticipated. Discussions continue to resolve the outstanding issues and
enable the Notified Body to issue the CE Mark for the product.

'CSD500, FLD500 and MED2002 are a related suite of products bearing the same
active compound as well as the same commercial partner. The market positioning
of these products is interdependent. We have agreed with our commercial partner
to focus on the launch of CSD500 first whilst continuing to develop the clinical
and commercial strategy for FLD500 and MED2002. In the meantime, design,
formulation and packaging work continues for these products.

'We are particularly encouraged by recent preliminary results from a clinical
study of TPR100, our topically applied pain relief product. In a comparative
study with the international market-leading OTC product, TPR100, which uses our
DermaSys(R) delivery platform, showed a substantial increase in the level of
active compound, an analgesic, transported through the skin compared with the
market-leading product. More information will be released once a full analysis
of the data has been completed. Discussions are on-going in connection with the
commercial rights to this product.

'In addition I would like to announce that, after six-and-a-half years with the
company, Anthony Clayden will be stepping down as Finance Director from the end
of May. I would like to thank Anthony for his very valuable contribution to
Futura and to wish him well for his new role as Chief Financial Officer at a
privately owned healthcare business.

'Derek Martin, Futura's Financial Controller appointed in April 2007, will
continue to oversee the finance function and will now assume the role of Company
Secretary.

'We are confident that Futura will continue to make significant progress during
the remainder of 2008 and beyond. We are a company on the threshold of revenues
from CSD500 and from other product opportunities based on our core DermaSys(R)
technology, the quality of which is underlined by the study results from our
TPR100 programme.'

For further information:

Futura Medical plc
James Barder, Chief Executive                           Tel: [phone]
mail to: [e-mail]                www.futuramedical.co.uk
                                                      --------------------------
Canaccord Adams
Ryan Gaffney / Adria Da Breo                            Tel: [phone]

Media enquiries:
Buchanan Communications
Mark Court / Rebecca Skye Dietrich                      Tel: [phone]

Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for
consumer healthcare. The Company is developing a portfolio of products and its
strategy is to license their manufacture and distribution to major
pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.
www.futuramedical.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange